GSK seeks to boost oncology repertoire with $5.1bn acquisition

GSK has agreed to buy US oncology company Tesaro for $5.1 billion (£4 billion), in a move designed to strengthen its anti-cancer offering.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Vaccines growth offsets Advair generic pain for GSK

25 July 2019 Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.

Americas

GSK and Merck KGaA unite in €3.7bn immunotherapy deal

6 February 2019 UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.

Big Pharma

GSK completes buyout of Novartis from joint venture

7 June 2018 GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

GSK seeks to boost oncology repertoire with $5.1bn acquisition

More on this story

Editor's picks

Editor's picks

More features